B. Riley Lifts Earnings Estimates for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities researchers at B. Riley upped their Q4 2025 earnings per share estimates for Eton Pharmaceuticals in a report released on Sunday, April 27th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings of $0.33 per share for the quarter, up from their previous estimate of $0.25. B. Riley currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. The firm had revenue of $11.65 million for the quarter, compared to analysts’ expectations of $10.53 million.

Other research analysts have also issued reports about the company. Craig Hallum upped their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the stock a “buy” rating in a report on Wednesday, March 19th. HC Wainwright restated a “buy” rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Price Performance

Shares of Eton Pharmaceuticals stock opened at $15.98 on Tuesday. The stock has a 50-day simple moving average of $14.07 and a 200-day simple moving average of $13.08. Eton Pharmaceuticals has a 52-week low of $3.18 and a 52-week high of $18.41. The firm has a market cap of $428.55 million, a price-to-earnings ratio of -72.64 and a beta of 1.34.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Point72 Asia Singapore Pte. Ltd. raised its stake in Eton Pharmaceuticals by 18.3% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock valued at $141,000 after acquiring an additional 1,634 shares during the period. XTX Topco Ltd lifted its stake in Eton Pharmaceuticals by 29.6% in the 4th quarter. XTX Topco Ltd now owns 14,655 shares of the company’s stock valued at $195,000 after purchasing an additional 3,351 shares during the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at about $86,000. Jefferies Financial Group Inc. bought a new stake in shares of Eton Pharmaceuticals in the fourth quarter worth $133,000. Finally, Bank of America Corp DE lifted its position in shares of Eton Pharmaceuticals by 5,422.4% in the 4th quarter. Bank of America Corp DE now owns 11,100 shares of the company’s stock worth $148,000 after purchasing an additional 10,899 shares during the period. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.